Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacology

Background:

• Percutaneous coronary interventions (PCI) have increased significantly for atherosclerotic coronary artery disease.
• PCI disrupts plaque and endothelium, activating platelets and coagulation, increasing ischemic complication risks.

Purpose of the Study:

• To comprehensively review the evolution of anti-platelet and anticoagulation regimens used in PCI.
• To summarize current understanding of coagulation and platelet activation in the context of PCI.

Main Methods:

• Review of scientific literature on anti-platelet and anti-thrombotic agents.
• Analysis of drug mechanisms of action and supporting clinical evidence for PCI use.
• Inclusion of AHA/ACC guideline recommendations for peri-PCI management.

Main Results:

• Discussion of the pivotal role of anti-platelet and anti-thrombotic agents in minimizing PCI-related ischemic events.
• Detailed examination of individual drug classes, their mechanisms, and evidence base.
• Presentation of guideline-based recommendations for peri-procedural therapy.

Conclusions:

• Anti-platelet and anticoagulation therapies are essential adjuncts to PCI.
• Understanding drug mechanisms and evidence is key to optimizing peri-PCI management.
• Adherence to guideline recommendations ensures effective prevention of ischemic complications.